Patents Represented by Attorney, Agent or Law Firm John Storella
  • Methods and devices for treating lung dysfunction
    Patent number: 7770577
    Abstract: Methods and devices useful for treatment of lung conditions resulting from dysfunction of normal pulmonary physiology.
    Type: Grant
    Filed: February 3, 2004
    Date of Patent: August 10, 2010
    Inventor: Gregory E Conner
  • Mammalian telomerase
    Patent number: 6258535
    Abstract: This invention is directed to compositions enriched for telomerase and methods of preparing the same.
    Type: Grant
    Filed: April 14, 1998
    Date of Patent: July 10, 2001
    Assignee: Geron Corporation
    Inventors: Bryant Villeponteau, Junli Feng, Walter Funk, William H. Andrews
  • Cross-reacting monoclonal antibodies specific for E-selectin and P-selectin
    Patent number: 6210670
    Abstract: This invention provides monoclonal antibodies that bind to both E-selectin and to P-selectin, and inhibit the binding of these proteins to counterreceptors. The invention also provides nucleic acids encoding these antibodies and methods for using the antibodies in the treatment of inflammatory conditions.
    Type: Grant
    Filed: March 26, 1996
    Date of Patent: April 3, 2001
    Assignee: Protein Design Labs, Inc.
    Inventor: Ellen L. Berg
  • Mammalian telomerase
    Patent number: 5837857
    Abstract: Nucleic acids comprising the RNA component of a mammalian telomerase are useful as pharmaceutical, therapeutic, and diagnostic reagents.
    Type: Grant
    Filed: June 5, 1996
    Date of Patent: November 17, 1998
    Assignee: Geron Corporation
    Inventors: Bryant Villeponteau, Junli Feng, Walter Funk, William H. Andrews
  • Antibodies and fragments thereof which bind the carboxyl-terminus of an amino-terminal fragment of .beta.APP
    Patent number: 5721130
    Abstract: Processing of .beta.-amyloid precursor protein (.beta.APP) is monitored by detecting the secretion of a soluble .beta.APP fragment resulting from cleavage of .beta.APP at the amino-terminus of .beta.-amyloid peptide. In vivo monitoring of secretion of the .beta.APP fragment may be monitored for diagnosis and prognosis of Alzheimer's disease and other .beta.-amyloid-related diseases, while in vitro monitoring of such secretion from cultured cells may be monitored to identify inhibitors of .beta.-amyloid production. The .beta.APP fragment may be detected using antibodies and other specific binding substances which recognize a carboxy-terminal residue on the fragment.
    Type: Grant
    Filed: May 12, 1995
    Date of Patent: February 24, 1998
    Assignees: Athena Neurosciences, Inc., Eli Lilly and Company
    Inventors: Peter A. Seubert, Dale B. Schenk, Lawrence C. Fritz